Welch P J, Tritz R, Yei S, Leavitt M, Yu M, Barber J
Immusol Inc, San Diego, CA 92121, USA.
Gene Ther. 1996 Nov;3(11):994-1001.
Two effective ribozymes (CR2 and CR4) that target HCV RNA 5' UTR and capsid gene regions were generated. Ribozyme cleavage was demonstrated in vitro, which can be enhanced by facilitator RNA molecules. In tissue culture cells, these two ribozymes can inhibit the expression of a cotransfected reporter gene containing HCV RNA target sequences. Furthermore, transduction of human hepatoma cells, HepG2, with retroviral vectors carrying CR2 or CR4 ribozymes enabled the cells to resist the infection by retroviral particles containing HCV target sequences. These results represent the first positive step towards the application of hairpin ribozymes in gene therapy for the treatment of HCV infection.
生成了两种靶向丙型肝炎病毒(HCV)RNA 5'非翻译区(UTR)和衣壳基因区域的有效核酶(CR2和CR4)。核酶切割在体外得到证实,促进RNA分子可增强这种切割作用。在组织培养细胞中,这两种核酶可抑制共转染的含有HCV RNA靶序列的报告基因的表达。此外,用携带CR2或CR4核酶的逆转录病毒载体转导人肝癌细胞HepG2,使这些细胞能够抵抗含有HCV靶序列的逆转录病毒颗粒的感染。这些结果代表了在将发夹核酶应用于基因治疗以治疗HCV感染方面迈出的第一个积极步骤。